Fundamental Data for GENZ

GENZYME-GE(NSDQ:GENZ)

Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company''s broad product portfolio is focused on rare genetic disorders, renal disease, and osteoarthritis, and includes an industry-leading array of diagnostic products and services. Genzyme''s commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need.

# Employees: 11000

Address: 500 Kendall Street,Cambridge,MA,USA

Phone: 617 252-7500

Fax: 617-494-6561

Website: www.genzyme.com

Email: information@genzyme.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

Henri A. Termeer (Chrmn.; Presi.; C.E.O.)

Zoltan A. Csimma (Sr. V.P. Human Res.)

Richard A. Moscicki M.D. (Sr. V.P. Clinic; Medical & Regul.; Chief Medic. Of)

Michael S. Wyzga (Exec. V.P. Fin.; Chief Acctg. & Finl. Off.)

Douglas A. Berthiaume (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/10/2010

Mean EPS (Next Qtr): $0.21

Mean EPS (Year): $1.74

Mean Estimate(Long Term): $18.67

P/E Ratio(Based on EPS estimate): 29.320

Number of Estimates: 11

Shares Performance

Period	GENZ	Compare to S&P
YTD	-23.05 %	-36.32 %
4 Weeks	0.93 %	-4.18 %
12 Weeks	-10.70 %	-16.84 %

Shares Information

Analyst Coverage: Y

Avg Volume: 4052388

Shares Outstanding: 270M

Market Cap: $13.80B

52 Week High: $73.21

52 Week Low: $48.19

P/E Ratio: 18.050

PEG Ratio: 1.570

Split: On 6/4/2001 GENZ split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: -53.73 %

EPS Growth in Last Year: -65.56 %

Sales Growth in Last Quarter: -13.92 %

Sales Growth in Last Quarter: -8.86 %

Financials

Qtr Book Value: $1.81

Cash Flow/Share: $10.20

Change in Payout Ratio: 0.000

Price/Sales: 3.000